Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

703 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Ramalingam SS, et al. Among authors: ohe y. N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21. N Engl J Med. 2020. PMID: 31751012 Free article. Clinical Trial.
Chemoradiotherapy for lung cancer.
Ohe Y. Ohe Y. Expert Opin Pharmacother. 2005 Dec;6(16):2793-804. doi: 10.1517/14656566.6.16.2793. Expert Opin Pharmacother. 2005. PMID: 16318430 Review.
Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib.
Takano T, Ohe Y, Tsuta K, Fukui T, Sakamoto H, Yoshida T, Tateishi U, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Matsuno Y, Furuta K, Tamura T. Takano T, et al. Among authors: ohe y. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5385-90. doi: 10.1158/1078-0432.CCR-07-0627. Clin Cancer Res. 2007. PMID: 17875767
Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer.
Fukui T, Ohe Y, Tsuta K, Furuta K, Sakamoto H, Takano T, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Asamura H, Tsuchida T, Kaneko M, Kusumoto M, Yamamoto S, Yoshida T, Tamura T. Fukui T, et al. Among authors: ohe y. Clin Cancer Res. 2008 Aug 1;14(15):4751-7. doi: 10.1158/1078-0432.CCR-07-5207. Clin Cancer Res. 2008. PMID: 18676744
EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan.
Takano T, Fukui T, Ohe Y, Tsuta K, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Furuta K, Tamura T. Takano T, et al. Among authors: ohe y. J Clin Oncol. 2008 Dec 1;26(34):5589-95. doi: 10.1200/JCO.2008.16.7254. Epub 2008 Sep 15. J Clin Oncol. 2008. PMID: 18794545
Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment.
Jida M, Toyooka S, Mitsudomi T, Takano T, Matsuo K, Hotta K, Tsukuda K, Kubo T, Yamamoto H, Yamane M, Oto T, Sano Y, Kiura K, Yatabe Y, Ohe Y, Date H, Miyoshi S. Jida M, et al. Among authors: ohe y. Cancer Sci. 2009 Oct;100(10):1931-4. doi: 10.1111/j.1349-7006.2009.01273.x. Epub 2009 Jul 2. Cancer Sci. 2009. PMID: 19650855 Free article.
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Mok TS, et al. Among authors: ohe y. N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19. N Engl J Med. 2009. PMID: 19692680 Free article. Clinical Trial.
703 results